Diagnosis and management of advanced hormone-refractory prostate cancer: Results of a practice survey on 301 French urologists;Diagnostic et prise en charge du cancer avancé de la prostate hormonorésistant: Résultats d'une enquête de pratique menée auprès de 301 urologues français

Progres en Urologie

Volumn 14, Issue 2, 2004, Pages 182-188

  Colombel, Marc ^a   Davin, Jean Louis ^b   Filleul, Annie ^c   Rousseau, Carine ^d  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Clinique Rhone Durance   (France)

^c Laboratoire Wyeth   (France)

^d Sylia Stat ^*  (France)

Author keywords

Chemotherapy; Hormonal escape; Horrmone refractory prostate cancer

Indexed keywords

MITOXANTRONE; PREDNISOLONE;

ADULT; AGED; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CARCINOMA; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW;

ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; FRANCE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS; QUESTIONNAIRES; TREATMENT FAILURE; UROLOGY;

EID: 3042681048     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. ALBERTSEN P.C., AARONSON N.K., MULLER M.J., KELLER S.D., WARE J.E. JR : Health-related quality of life among patients with metastatic prostate cancer. Urology, 1997 ; 49 : 207-216.
2. CULINE S. : place de la mitoxantrone dans la prise en charge du cancer de prostate métastatique hormono-indépendant. Progrès en urologie, 2002 ; Suppl 2 : 31-35.
3. DUPONT A., GOMEZ J.L., CUSAN L., KOUTSILIERIS M., LABRIE F. : Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol., 1993 ; 150 : 908-913.
4. FIGG W.D., SARTOR O., COOPER M.R., THIBAULT A., BERGAN R.C., DAWSON N., REED E., MYERS C.E. : Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostatic cancer. Am. J. Med., 1995 ; 98 : 412-414.
5. GOODIN S., KAMAKSHI V.R., DIPAOLA R.S. : State of the art treatment of metastatic hormone-refractory prostate cancer. The oncologist, 2002 ; 7 : 360-370.
6. HALABY S., SMALL E.J., KANTOFF P.W., KATTAN M.W., KAPLAN E.B., DAWSON N.A., LEVINE E.G., BLUMENSTEIN B.A., VOGELZANG N.J. : Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. JCO, 2003 ; 21 : 1232-1236.
7. HARRIS K.A., REESE D.M. : Treatment options in hormone-refractory prostate cancer. Drugs, 2001 ; 61 : 2177-2192.
8. HUGGINS C. : the effect of castration, of oestrogen and androgen injection on serum phosphates in metastatic carcinoma of the prostate. Cancer Res., 1941 ; 1 : 293-297.
9. KELLY W.K., SCHER H.I., MAZUMDAR M., VLAMIS V., SCHWARTZ M., FOSSA S.D. : Prostate specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. JCO, 1993 ; 11 : 607-615.
10. KNOX J.J., MOORE M.J. : Treatment of hormone refractory prostate. Cancer. Sem in Urol. Oncol., 2001 ; 19 : 202-211.
11. MCDERMOTT R.S., ROSS E., HAAS N., UZZO R., GREENBERG R., HUDES G. : A prognostic model for survival in androgen independent prostate cancer. ASCO 2003 : abstract 1610.
12. MOORE M.J., OSOBA D., MURPHY K., TANNOCK I.E., ARMITAGE A., FINDLAY B., COPPIN C., NEVILLE A., VENNER P., WILSON J. : Use of palliative endpoints to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer-JCO, 1994 ; 12 (4) : 689-94
13. NEWLING D.W., DENIS L., VERMEYLEN K. : Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer; analysis of the criteria of evaluation used in European Organization for research and treatment of Cancer-genitourinary group. Cancer, 1993 ; 72 : 3793-3798.
14. OSOBA D., TANNOCK I.F., ERNST D.S., NEVILLE A.J. : Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. JCO, 1999 ; 17 : 1654-1663.
15. REBILLARD X., VILLERS A., RUFFION A., BEUZEBOX P., SOULIÉ A., RICHAUD P., BARRÉ B., ESCHWEGE P., FONTAINE E., MOLINIÉ V., MOREAU J.L., PENEAU M., RAVERY V., STAERMAN F. ET LE COMITÉ DE CANCÉROLOGIE DE L'AFU : Recommendations 2002 sur le cancer de la prostate. Progrès en urologie, 2002 ; 12 : 31-67.
16. RINI B.I., SMALL E.J. : Hormone-refractory prostate cancer-Current treatment options in oncology, 2002 ; 3 : 437-446.
17. SARTOR O. : Endpoints in prostate cancer clinical trials. Urology, 2002 ; 60 : 101-108.
18. SCHER H.I., GUNNAR STEINECK, KELLY W.K. : Hormone-refractory (D3) prostate cancer : refining the concept. Urology, 1995 ; 46 : 142-148.
19. SCHER H.I., KELLY W.M., ZHANG Z.F., OUYANG P., SUN M., SCHWARTZ M., DING C., WANG W., HORAK I.D., KREMER A.B. : Post-therapy serum prostatic specific antigen level and survival in patients with androgen-independent prostate cancer. J. Natl. Cancer inst., 1999 ; 91 : 244-251.
20. SCHMID H.P., MORANT R., BERNHARD J., MAIBACH R. : Prostate specific antigen doubling time as auxilliary end point in hormone refractory prostatic carcinoma. Eur. Urology, 2003 ; 43 : 28-30.
21. SERRETTA V., RIZZO I., CONTINO G., PAVONE C., POMARA G., MELLONI D., PAVONE-MACALUSO M. : PSA and second line therapy of hormone refractory prostate carcinoma. Urol. Int., 2001 ; 66 : 131-134.
22. SMALL E.J., SRINIVAS S. : The anti-androgen withdrawal syndrome : experience in a large cohort of unselected patients with advanced prostate cancer. Cancer, 1995 ; 76 : 1428-1434.
23. SMITH D.C., DUNN R.L., STRAWDERMAN M.S., PIENTA K.J. : Change in serum specific antigen as a marker of response to cytotoxic therapy for hormone refractory prostate cancer. JCO, 1998 ; 16 : 1835-1843.
24. SOULIÉ M., VILLERS A., GROSCLAUDE P., MENEGOZ P., SCHAFFER P., MACE-LESEC'H J., SAUVAGE-MACHELARD M., MOLINIER L. ET GRAND A. : Le cancer de la prostate en France : resultats de l'enquête CCAFU-FRANCIM. Progrès en urologie, 2001 ; 11 : 478-485.
25. TANNOCK I.F., OSOBA D., STOCKLER M.R., ERNST D.S., NEVILLE A.J., MOORE M.J., ARMITAGE G.R., WILSON J.J., VENNER P.M., COPPIN C.M., MURPHY K.C. : Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer : a Canadian randomized Trial with palliative End points. JCO, 1996 ; 14 : 1756-1764.
26. WASELENKO J.K., DAWSON N.A. : Management of progressive metastatic prostate cancer. Oncology, 1997 ; 11 : 1551-1560.